Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Cancer J Clin. 2022;72(1):7–33 PubMed PMID: 35020204. Epub 2022/01/13. eng.

Article  Google Scholar 

Nagarajan D, McArdle SEB. Immune Landscape of breast cancers. Biomedicines. 2018;6(1):20. PubMed PMID: 29439457. Pubmed Central PMCID: PMC5874677. Epub 2018/02/15. eng.

Makhoul I, Atiq M, Alwbari A, Kieber-Emmons T. Breast Cancer Immunotherapy: an update. Breast cancer: Basic and Clinical Research. 2018;12:1178223418774802 (PubMed PMID: 29899661. Pubmed Central PMCID: PMC5985550. Epub 2018/06/15. eng).

PubMed  Google Scholar 

Zhu X, Ying J, Wang F, Wang J, Yang H. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive Breast cancer: a 3,198 cases study at National Cancer Center, China. Breast Cancer Res Treat. 2014;147(3):551–5 (PubMed PMID: 25234844. Epub 2014/09/23. eng).

Article  CAS  PubMed  Google Scholar 

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative Breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011;121(7):2750–67 (PubMed PMID: 21633166. Pubmed Central PMCID: PMC3127435. Epub 2011/06/03. eng).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen X, Xu D, Li X, Zhang J, Xu W, Hou J, et al. Latest overview of the cyclin-dependent kinases 4/6 inhibitors in Breast Cancer: the past, the Present and the future. J Cancer. 2019;10(26):6608–17 (PubMed PMID: 31777590. Pubmed Central PMCID: PMC6856891. Epub 2019/11/30. eng).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takada M, Toi M. Neoadjuvant treatment for HER2-positive Breast cancer. Chin Clin Oncol. 2020;9(3):32 (PubMed PMID: 32527117. Epub 2020/06/13. eng).

Article  PubMed  Google Scholar 

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative Breast cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2008;26(8):1275–81 (PubMed PMID: 18250347. Epub 2008/02/06. eng).

Article  Google Scholar 

DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. Cancer J Clin. 2019;69(6):438–51 (PubMed PMID: 31577379. Epub 2019/10/03. eng).

Article  Google Scholar 

Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, et al. The global burden of women’s cancers: a grand challenge in global health. Lancet (London England). 2017;389(10071):847–60 (PubMed PMID: 27814965. Pubmed Central PMCID: PMC6191029. Epub 2016/11/07. eng).

Article  PubMed  Google Scholar 

Parkes A, Clifton K, Al-Awadhi A, Oke O, Warneke CL, Litton JK, et al. Characterization of bone only Metastasis patients with respect to Tumor subtypes. NPJ Breast cancer. 2018;4:2 (PubMed PMID: 29387785. Pubmed Central PMCID: PMC5785511. Epub 2018/02/02. eng).

Article  PubMed  PubMed Central  Google Scholar 

O’Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for Breast cancer. Cochrane Database Syst Rev. 2017;10(10):Cd003474 (PubMed PMID: 29082518. Pubmed Central PMCID: PMC6485886 AG: none known. Epub 2017/10/31. eng).

PubMed  Google Scholar 

Fang J, Xu Q. Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics. Clinical & translational oncology: official publication of the Federation of. Span Oncol Soc Natl Cancer Inst Mexico. 2015;17(3):173–9 (PubMed PMID: 25351174. Epub 2014/10/30. eng).

CAS  Google Scholar 

Kuchuk I, Hutton B, Moretto P, Ng T, Addison CL, Clemons M. Incidence, consequences and treatment of bone metastases in Breast cancer patients-experience from a single cancer centre. J bone Oncol. 2013;2(4):137–44 (PubMed PMID: 26909284. Pubmed Central PMCID: PMC4723382. Epub 2013/12/01. eng).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee SJ, Park S, Ahn HK, Yi JH, Cho EY, Sun JM, et al. Implications of bone-only metastases in Breast cancer: favorable preference with excellent outcomes of hormone receptor positive Breast cancer. Cancer Res Treat. 2011;43(2):89–95 (PubMed PMID: 21811424. Pubmed Central PMCID: PMC3138922. Epub 2011/08/04. eng).

Article  PubMed  PubMed Central  Google Scholar 

Thanopoulou E, Khader L, Caira M, Wardley A, Ettl J, Miglietta F, et al. Therapeutic strategies for the management of hormone Receptor-Positive, human epidermal growth factor receptor 2-Positive (HR+/HER2+) Breast Cancer: a review of the current literature. Cancers. 2020;12(11): 3317 (PubMed PMID: 33182657. Pubmed Central PMCID: PMC7696181. Epub 2020/11/14. eng).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Invernizzi M, Kim J, Fusco N. Editorial. Quality of life in Breast Cancer patients and survivors. Front Oncol. 2020;10.

Article  PubMed  PubMed Central  Google Scholar 

Baek YH, Jeon HL, Oh IS, Yang H, Park J, Shin JY. Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone Metastasis or Multiple Myeloma: a 12-year longitudinal nationwide healthcare database study. Cancer Epidemiol. 2019;61:104–10 (PubMed PMID: 31176960. Epub 2019/06/10. eng).

Article  PubMed  Google Scholar 

D’Oronzo S, Wood S, Brown JE. The use of bisphosphonates to treat skeletal Complications in solid tumours. Bone. 2021;147:115907 (PubMed PMID: 33676057. Epub 2021/03/07. eng).

Article  PubMed  Google Scholar 

Guise TA. Breast cancer bone metastases: it’s all about the neighborhood. Cell. 2013;154(5):957–9 (PubMed PMID: 23993088. Epub 2013/09/03. eng).

Article  CAS  PubMed  Google Scholar 

Invernizzi M, Venetis K, Sajjadi E, Piciotti R, de Sire A, Fusco N. Understanding the biology of volumetric muscle loss for an individualized exercise rehabilitation approach in Breast cancer patients. Curr Opin Pharmacol. 2021;58:27–34 (PubMed PMID: 33848933. Epub 2021/04/14. eng).

Article  CAS  PubMed  Google Scholar 

Invernizzi M, de Sire A, Fusco N. Rethinking the clinical management of volumetric muscle loss in patients with spinal cord injury: synergy among nutritional supplementation, pharmacotherapy, and rehabilitation. Curr Opin Pharmacol. 2021;57:132–9 (PubMed PMID: 33721616. Epub 2021/03/16. eng).

Article  CAS  PubMed  Google Scholar 

Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome biology. 2017;18(1):220. PubMed PMID: 29141660. Pubmed Central PMCID: PMC5688663 The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Epub 2017/11/17. eng.

Article  PubMed  PubMed Central  Google Scholar 

Hänzelmann S, Castelo R, Guinney J. BMC Bioinformatics. 2013;14: 7 (PubMed PMID: 23323831. Pubmed Central PMCID: PMC3618321. Epub 2013/01/18. eng. GSVA: gene set variation analysis for microarray and RNA-seq data).

Article  PubMed  PubMed Central  Google Scholar 

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Proc Natl Acad Sci USA. 2005;102(43):15545–50 (PubMed PMID: 16199517. Pubmed Central PMCID: PMC1239896. Epub 2005/10/04. eng. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7 (PubMed PMID: 22455463. Pubmed Central PMCID: PMC3339379. Epub 2012/03/30. eng).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Colwill K, Gräslund S. A roadmap to generate renewable protein binders to the human proteome. Nat Methods. 2011;8(7):551–8 (PubMed PMID: 21572409. Epub 2011/05/17. eng).

Article  CAS  PubMed  Google Scholar 

Ren X, Chen X, Ji Y, Li L, Li Y, Qin C, et al. Upregulation of KIF20A promotes Tumor proliferation and invasion in renal clear cell carcinoma and is associated with adverse clinical outcome. Aging. 2020;12(24):25878–94 (PubMed PMID: 33232285. Pubmed Central PMCID: PMC7803492. Epub 2020/11/25. eng).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fu A, Yu Z, Zhang E, Song J. Long noncoding RNA ZBED3-AS1 restrains Breast cancer progression by targeting the microRNA-513a-5p/KLF6 axis. Thorac cancer. 2021;12(20):2719–31 (PubMed PMID: 34427978. Pubmed Central PMCID: PMC8520814. Epub 2021/08/25. eng).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jatoi I, Miller AB. Why is Breast-cancer mortality declining? Lancet Oncol. 2003;4(4):251–4 (PubMed PMID: 12681269. Epub 2003/04/12. eng).

Article  PubMed  Google Scholar 

Coughlin SS. Epidemiology of Breast Cancer in women. Advances in experimental medicine and biology. 2019;1152:9–29 PubMed PMID: 31456177. Epub 2019/08/29. eng.

Article  CAS  PubMed  Google Scholar 

Emens LA. Breast Cancer Immunotherapy: Facts and Hopes. Clinical cancer research: an official journal of the American Association for. Can Res. 2018;24(3):511–20 (PubMed PMID: 28801472. Pubmed Central PMCID: PMC5796849. Epub 2017/08/13. eng).

CAS  Google Scholar 

Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40 (PubMed PMID: 36810079. Pubmed Central PMCID: PMC9942077. Epub 2023/02/23. eng).

Article  PubMed  PubMed Central  Google Scholar 

Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541–7 (PubMed PMID: 7584144. Epub 1995/11/01. eng).

Article  CAS  PubMed  Google Scholar 

Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol. 2007;19(3):309–14 (PubMed PMID: 17433872. Epub 2007/04/17. eng).

Article  CAS  PubMed  Google Scholar 

Vranic S, Cyprian FS, Gatalica Z, Palazzo J. PD-L1 status in Breast cancer: current view and perspectives. Sem Cancer Biol. 2021;72:146–54 (PubMed PMID: 31883913. Epub 2019/12/31. eng).

Article  Google Scholar 

Narod SA, Salmena L. BRCA1 and BRCA2 mutations and Breast cancer. Discov Med. 2011;12(66):445–53 (PubMed PMID: 22127115. Epub 2011/12/01. eng).

PubMed  Google Scholar 

Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations on Breast cancer prognosis: a systematic review and meta-analysis. Medicine. 2016;95(40): e4975 (PubMed PMID: 27749552. Pubmed Central PMCID: PMC5059054. Epub 2016/10/18. eng).

Article  CAS  PubMed